Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 449Carcinoma, Non-Small-Cell Lung 372Neoplasms 349Prostatic Neoplasms 285Colorectal Neoplasms 273Multiple Myeloma 211Lung Neoplasms 201Neoplasm Metastasis 185Leukemia, Myeloid, Acute 163Ovarian Neoplasms 159Pancreatic Neoplasms 155Squamous Cell Carcinoma of Head and Neck 140Melanoma 131Recurrence 108Glioblastoma 105Head and Neck Neoplasms 103Carcinoma, Renal Cell 103Endometrial Neoplasms 100Precursor Cell Lymphoblastic Leukemia-Lymphoma 97Lymphoma, Non-Hodgkin 95Stomach Neoplasms 94Carcinoma, Hepatocellular 94Lymphoma 93Triple Negative Breast Neoplasms 92Brain Neoplasms 90Uterine Cervical Neoplasms 86Lymphoma, Large B-Cell, Diffuse 81Glioma 79Urinary Bladder Neoplasms 78Sarcoma 78

Interventions

Sodium Chloride 1Amiodarone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Atrial Fibrillation × 30 days × Clear all
NCT06067438 2026-05-22

Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer

OHSU Knight Cancer Institute

Phase 2 Recruiting
90 enrolled
Gastrointestinal

Atrial Fibrillation, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡